Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$80.03 USD

80.03
2,683,285

-1.78 (-2.18%)

Updated Aug 5, 2024 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Mark Vickery headshot

Yes Virginia, There Is a Santa Claus Rally

by Mark Vickery

The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.

Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod

by Zacks Equity Research

FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate

by Kinjel Shah

FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

by Zacks Equity Research

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More

by Kinjel Shah

Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.

The Zacks Analyst Blog Highlights Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources

by Zacks Equity Research

Adobe, AstraZeneca, Intel, Morgan Stanley and EOG Resources are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Adobe, AstraZeneca & Intel

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), AstraZeneca PLC (AZN) and Intel Corporation (INTC).

LLY Down as Patients Regain Weight After Stopping Zepbound

by Zacks Equity Research

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.

AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.

Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study

by Zacks Equity Research

After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.

Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus

by Zacks Equity Research

Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.

Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

by Zacks Equity Research

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

by Zacks Equity Research

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

by Zacks Equity Research

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

Novo Nordisk (NVO) to Expand Manufacturing Site in France

by Zacks Equity Research

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why Astrazeneca (AZN) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

by Zacks Equity Research

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use

by Kinjel Shah

FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication